| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 05/10/2002 | WO2002036611A2 Immunomodulatory peptides derived from heat shock proteins and uses thereof |
| 05/10/2002 | WO2002036551A1 Peptide derivatives and their pharmaceutically acceptable salts, processes for preparation of both, and use thereof |
| 05/10/2002 | WO2002036175A2 Sustained release device for treating conditions of the joint |
| 05/10/2002 | WO2002036171A1 Methods for enhancing the efficacy of cytotoxic agents through the use of hsp90 inhibitors |
| 05/10/2002 | WO2002036170A2 Vector system for transducing the positive neurons |
| 05/10/2002 | WO2002036169A2 Methods and compositions for enhanced delivery of bioactive molecules |
| 05/10/2002 | WO2002036166A2 Compositions for stimulating cd45 and thereby suppressing microglial activation associated with alzheimer's disease |
| 05/10/2002 | WO2002036162A2 Compositions for treatment of ocular neovascularization and neural injury |
| 05/10/2002 | WO2002036158A1 Suspension of an epi-hne protein, process of preparation thereof, dry powder aerosol derived therefrom, pharmaceutical compositions containing said suspension or aerosol, and their uses |
| 05/10/2002 | WO2002036157A1 Use of melagatran for manufacture of a medicament for the treatment of ischemic disorders |
| 05/10/2002 | WO2002036156A1 Use of enzymes obtained from ciliates as medicaments for promoting digestion |
| 05/10/2002 | WO2002036155A1 Use of blood coagulation factor xiii for treating haemophilia a |
| 05/10/2002 | WO2002036154A2 Procollagen (iii) propeptides and related substances for treating fibrotic diseases |
| 05/10/2002 | WO2002036152A1 Use of il-1 inhibitors and tnf antagonists, partially in combination with recombinant erythropoietins, for the treatment of anemia |
| 05/10/2002 | WO2002036151A2 Use of the long pentraxin ptx3 for the preparation of medicament for the prevention and cure of autoimmune pathologies |
| 05/10/2002 | WO2002036150A1 Gene-digesting gene and enzyme having vaccine-like effect |
| 05/10/2002 | WO2002036149A2 Methods for obtaining inhibitors of t-cell membrane protein (tirc7) ligand binding and uses thereof |
| 05/10/2002 | WO2002036148A2 Use of death receptor ligands or rip to initiate the non-caspase-dependent cell death and compounds for inhibition of the non-caspase-dependent cell death |
| 05/10/2002 | WO2002036147A1 Mineralized collagen-polysaccharide matrix for bone and cartilage repair |
| 05/10/2002 | WO2002036146A2 Epitope-beta microglobulin polynucleotide for anti-cancer immunotherapy |
| 05/10/2002 | WO2002036145A2 Kahalalide f formulation |
| 05/10/2002 | WO2002036144A1 Gnrh analogues for treatment of urinary incontinence |
| 05/10/2002 | WO2002036143A1 Inhibition or reversal of skin aging by actin-sequestering peptides |
| 05/10/2002 | WO2002036142A2 Compositions for inhibiting grb7 |
| 05/10/2002 | WO2002036141A2 Method of enhancing lymphocyte-mediated immune responses |
| 05/10/2002 | WO2002036136A2 Compositions and methods for prolonging survival of chilled platelets |
| 05/10/2002 | WO2002036131A1 In vivo stimulation of angiogenic activity |
| 05/10/2002 | WO2002036108A2 Use of 20-hete synthesizing enzyme inhibitors as therapy for cerebral vascular diseases |
| 05/10/2002 | WO2002036078A2 Targeting pluripotent stem cells to tissues |
| 05/10/2002 | WO2002036072A2 Method for short-term and long-term drug dosimetry |
| 05/10/2002 | WO2002035981A2 Methods and compositions for the treatment of human immunodeficiency virus infection |
| 05/10/2002 | WO2002035942A1 Food grade transglutaminase inhibitor and uses thereof |
| 05/10/2002 | WO2002020057A3 Flavoring systems for pharmaceutical compositions and methods of making such compositions |
| 05/10/2002 | WO2002016381A3 Composition and method for inhibiting platelet aggregation |
| 05/10/2002 | WO2002015927A8 High mannose proteins and methods of making high mannose proteins |
| 05/10/2002 | WO2002014537A3 Methods for diagnosing and treating dysautonomia and other dysautonomic conditions |
| 05/10/2002 | WO2002011743B1 Treatment of prostate cancer |
| 05/10/2002 | WO2002009668A3 Pulmonary administration of flint |
| 05/10/2002 | WO2002009641A3 Promyostatin peptides and methods of using same |
| 05/10/2002 | WO2002007676A3 Compounds having affinity for the granulocyte-colony stimulating factor receptor (g-csfr) |
| 05/10/2002 | WO2002004492A3 Herpes zinc finger motifs |
| 05/10/2002 | WO2002000821A3 A novel polypeptide, a human protein plp39 and the polynucleotide encoding the polypeptide |
| 05/10/2002 | WO2002000246A3 Preparation containing an oxygen carrier for regeneration of the skin in the case of oxygen deficiency |
| 05/10/2002 | WO2001096526A3 A novel polypeptide, a human tumor suppressor factor 11.77 and the polynucleotide encoding the polypeptide |
| 05/10/2002 | WO2001093890B1 Botulinum toxin implant |
| 05/10/2002 | WO2001093827B1 Neurotoxin implant |
| 05/10/2002 | WO2001092337A3 Soluble ctla4 mutant molecules and uses thereof |
| 05/10/2002 | WO2001089564A3 Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity |
| 05/10/2002 | WO2001089282A3 2-amino-3-hydroxy-4-tert-leucyl-amino-5-phenyl-pentanoic acid amide derivatives |
| 05/10/2002 | WO2001088116A3 Method of modulating activation of lymphocytes via modulation of pituitary tumor transforming gene, related screeining methods |
| 05/10/2002 | WO2001085920A3 Compositions and methods for producing antigen-presenting cells |
| 05/10/2002 | WO2001085201A3 Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis |
| 05/10/2002 | WO2001083750A3 Dendritic cell co-stimulator molecules |
| 05/10/2002 | WO2001082946A3 Neuroprotective compositions |
| 05/10/2002 | WO2001079539A3 Method for using transfectable constructions from luciferase and from the promotor of the human period 1 gene for identifying novel active substances that influence the day/night rhythm and sleep |
| 05/10/2002 | WO2001079469A3 Cloning of corynebacteriaceae histidine ammonia lyase and therapeutic uses |
| 05/10/2002 | WO2001079288A3 Cytokine uses; compositions; methods |
| 05/10/2002 | WO2001077145A3 Integrin binding peptide derivatives |
| 05/10/2002 | WO2001076639A3 Chemically-modified myelopoietin conjugates |
| 05/10/2002 | WO2001070808A3 Angiogenesis - associated proteins, and nucleic acids encoding the same |
| 05/10/2002 | WO2001068697A3 Methods and compositions for immunoregulation |
| 05/10/2002 | WO2001068677A3 Derivatives of breast canacer antigen her-2 for therapeutical use |
| 05/10/2002 | WO2001068135A3 Compositions and methods for affecting osteogenesis |
| 05/10/2002 | WO2001066742A3 G-protein coupled receptors |
| 05/10/2002 | WO2001064908A3 14790, a protein kinase and uses therefor |
| 05/10/2002 | WO2001064879A3 G-proteins coupled receptor related polypeptides |
| 05/10/2002 | WO2001064236A3 METHODS FOR TREATING FSH RELATED CONDITIONS WITH GnRH ANTAGONISTS |
| 05/10/2002 | WO2001064031A3 Slpi knockout mice and methods for wound treatment |
| 05/10/2002 | WO2001055339A3 Novel fetal nucleic acids and polypeptides |
| 05/10/2002 | WO2001055323A3 Nucleic acids, proteins, and antibodies |
| 05/10/2002 | WO2001048190A3 Therapeutic uses of lna-modified oligonucleotides |
| 05/10/2002 | WO2001047963A3 Inhibitors of complement activation, their preparation and use |
| 05/10/2002 | WO2001047955A3 Improvements in or relating to immune responses to hiv |
| 05/10/2002 | WO2001046455A3 Survivin promotion of angiogenesis |
| 05/10/2002 | WO2001046420A3 Il-17 and il-17r homologous polypeptides and therapeutic uses thereof |
| 05/10/2002 | WO2001042472A3 DNA ENCODING A NOVEL PROST-Ets POLYPEPTIDE |
| 05/10/2002 | WO2001042296A3 Clasp-5 transmembrane protein |
| 05/10/2002 | WO2001042284A3 Protein comprising ig-like domain 4 of a vegf receptor mediates receptor dimerization, but not activation |
| 05/10/2002 | WO2001041780A3 Use of an immunosuppressant for increasing an antifugal activity of a lipopeptide |
| 05/10/2002 | WO2001040466A3 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 05/10/2002 | WO2001040142A3 P21 derived peptides capable of inhibiting cdk/cyclin complexes |
| 05/10/2002 | WO2001039792A3 The use of caspase 9 inhibitors to treat ocular neural pathology |
| 05/10/2002 | WO2001038351A3 Nucleotide sequence of the shrimp white spot syndrome bacilliformvirus (wsbv), systems containing this sequence and detection kits |
| 05/10/2002 | WO2001038349A3 NOVEL ss-DEFENSINS |
| 05/10/2002 | WO2001037784A3 Method for preventing irinotecan induced diarrhea |
| 05/10/2002 | WO2001036638A3 Polypeptides and nucleic acids encoding same |
| 05/10/2002 | WO2001036486A3 Scfv antibodies against disease associated molecules |
| 05/10/2002 | WO2001036467A3 Mammalian receptor proteins; related reagents and methods |
| 05/10/2002 | WO2001036446A3 Use of g-protein coupled receptors (gpcrs) and modified gpcrs for the treatment of diseases |
| 05/10/2002 | WO2001036432A3 18 human secreted proteins |
| 05/10/2002 | WO2001034641A8 Antimicrobial activity of the first cationic cluster of human lactoferrin |
| 05/10/2002 | WO2001034157A9 Protease inhibitors |
| 05/10/2002 | WO2001032709A3 Polypeptides with non-natural primary signalling motifs |
| 05/10/2002 | WO2001031007A9 Nucleic acid molecules derived from rat brain and programmed cell death models |
| 05/10/2002 | WO2001030972A3 Regulation of gene expression by neuroleptic agents |
| 05/10/2002 | WO2001028580A3 Modulation of angiogenesis |
| 05/10/2002 | WO2001026643A9 Inhibition of tumorigenic properties of melanoma cells |
| 05/10/2002 | WO2001025271A3 Fibroblast growth factor-5 (fgf-5) is a tumor associated t-cell antigen |
| 05/10/2002 | WO2001024827A3 INHIBITORS OF THE ENDOTHELIN SIGNALLING PATHWAY AND αVβ3 INTEGRIN RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY |
| 05/10/2002 | WO2001024784A3 New use |